ArticleThe Journal of antimicrobial chemotherapy2015
Added value of whole-genome sequencing for management of highly drug-resistant TB.
Article in The Journal of antimicrobial chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03237182 (The Individualized M), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Individualized M(X) Drug-resistant TB Treatment Strategy Study A Strategy to Improve Treatment Outcomes in Patients With Drug-resistant TB
Who cites it
18 citing papers in PubMed.
- A Retrospective Analysis Examining the Impact of Educational Attainment and Social Determinants of Health on Rifampicin-Resistant Tuberculosis Treatment Outcomes.Open forum infectious diseases · 2026Article
- Body mass index (BMI) at RR-TB diagnosis as an independent predictor of treatment outcomes: a retrospective analysis.BMC infectious diseases · 2026Article
- Article
- Diagnosis and Management of Multidrug-Resistant Tuberculosis in Children: A Practical Approach.Indian journal of pediatrics · 2019Review
- Key Issues in the Management of Multi-Drug Resistant Tuberculosis: A Case Report.Open access Macedonian journal of medical sciences · 2018Article
- Molecular Diagnosis of Tuberculosis.Chonnam medical journal · 2018Review
- Whole-Genome Sequencing of Bacterial Pathogens: the Future of Nosocomial Outbreak Analysis.Clinical microbiology reviews · 2017Review
- A joint cross-border investigation of a cluster of multidrug-resistant tuberculosis in Austria, Romania and Germany in 2014 using classic, genotyping and whole genome sequencing methods: lessons learnt.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2017Article
- Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.Antimicrobial agents and chemotherapy · 2016Article
- Rapid Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates Directly from Clinical Samples by Use of Amplicon Sequencing: a Proof-of-Concept Study.Journal of clinical microbiology · 2016Article
- High rate of drug resistance among tuberculous meningitis cases in Shaanxi province, China.Scientific reports · 2016Article
- Methodological and Clinical Aspects of the Molecular Epidemiology of Mycobacterium tuberculosis and Other Mycobacteria.Clinical microbiology reviews · 2016Review
- Diagnostic 'omics' for active tuberculosis.BMC medicine · 2016Review
- Clinical use of whole genome sequencing for Mycobacterium tuberculosis.BMC medicine · 2016Review
- Utility of Whole-Genome Sequencing of Escherichia coli O157 for Outbreak Detection and Epidemiological Surveillance.Journal of clinical microbiology · 2015Article
- Collaborative Effort for a Centralized Worldwide Tuberculosis Relational Sequencing Data Platform.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Article
- Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences.Genome medicine · 2015Article
- Evaluation of resistance acquisition during tuberculosis treatment using whole genome sequencing.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPhenotypic drug susceptibility testing (DST) for Mycobacterium tuberculosis takes several weeks to complete and second-line DST is often poorly reproducible, potentially leading to compromised clinical decisions. Following a fatal case of XDR TB, we investigated the potential benefit of using whole-genome sequencing to generate an in silico drug susceptibility profile.
methodsThe clinical course of the patient was reviewed, assessing the times at which phenotypic DST data became available and changes made to the therapeutic regimen. Whole-genome sequencing was performed on the earliest available isolate and variants associated with drug resistance were identified.
resultsThe final DST report, including second-line drugs, was issued 10 weeks after patient presentation and 8 weeks after initial growth of M. tuberculosis. In the interim, the patient may have received a compromised regimen that had the potential to select for further drug resistance. The in silico susceptibility profile, extrapolated from evolving evidence in the literature, provided comparable or superior data to the DST results for second-line drugs and could be generated in a much shorter timeframe.
conclusionsWe propose routine whole-genome sequencing of all MDR M. tuberculosis isolates in adequately resourced settings. This will improve individual patient care, monitor for transmission events and advance our understanding of resistance-associated mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.